NFLECTION THERAPEUTICS
NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi and nevus sebaceous. To address these rare disorders, which are also referred to as RASopathies because they are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, NFlection develops first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments.
NFLECTION THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.nflectionrx.com
Total Employee:
1+
Status:
Active
Contact:
617-875-4559
Total Funding:
41.4 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Aptitude Medical Systems
Aptitude Medical Systems focuses on the potential of aptamers to solve the fundamental problems of antibodies.
HepaTx
Hepatx is developing regenerative medicine solutions.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Zavante Therapeutics
Zavante focuses on developing novel therapies to improve the outcomes of hospitalized patients.
Current Employees Featured
Christopher Powala President & Chief Eexecutive Officer @ NFlection Therapeutics
President & Chief Eexecutive Officer
2019-06-01
Mike Wootton Co-Founder and Chief Executive Officer @ NFlection Therapeutics
Co-Founder and Chief Executive Officer
Founder
Investors List
F-Prime Capital
F-Prime Capital investment in Series A - NFlection Therapeutics
venBio Partners
venBio Partners investment in Series A - NFlection Therapeutics
Eight Roads Ventures
Eight Roads Ventures investment in Venture Round - NFlection Therapeutics
Official Site Inspections
http://www.nflectionrx.com
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "NFlection Therapeutics"
Home - NFlection Therapeutics
NFlection is a clinical-stage biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant …See details»
Overview - NFlection Therapeutics
We are a clinical-stage biotechnology company focused on the discovery and development of targeted therapies for skin disorders driven by aberrant activation of the RAS pathway.See details»
NFlection Therapeutics - Crunchbase Company Profile …
View contacts for NFlection Therapeutics to access new leads and connect with decision-makers. NFlection Therapeutics is a biopharmaceutical company focusing on targeted treatments for rare diseases.See details»
Overview - NFlection Therapeutics
NFlection was founded with the mission of developing proprietary, novel compounds that are highly selective mitogen-activated protein kinase kinase (MEK) inhibitors to mitigate or treat cutaneous neurofibromas in …See details»
NFlection Therapeutics - LinkedIn
NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell...See details»
NFlection Therapeutics - PitchBook
Developer of novel therapies designed for doctors to cure disorders driven by aberrant activation of the RAS pathway.See details»
NFlection Therapeutics Launches with $20M Series A Funding to …
Jun 9, 2020 · NFlection's topical MEK inhibitors are designed to degrade rapidly in circulation to avoid systemic side effects. To learn more about the company, please visit …See details»
NFlection Therapeutics Seeking Adult Patients for Investigational …
To learn more about this clinical trial and to be connected to available clinic sites, visit https://www.nflectionrx.com/. Anyone considering participating in a clinical trial should discuss …See details»
NFlection Therapeutics Appoints William Hodder as …
Oct 18, 2021 · WAYNE, Pa.-- ( BUSINESS WIRE )--NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for rare RASopathies, today announced that it...See details»
Management - NFlection Therapeutics
William Hodder joined NFlection in October 2021 as Chief Executive Officer, bringing more than 35 years of broad biopharmaceutical industry experience including fundraising, business development, corporate and product …See details»
NFlection Therapeutics - VentureRadar
Website: https://www.nflectionrx.com/ Develops targeted therapies for rare RASopathies disorders using first-in-class soft MEK inhibitors as topical treatments for neurofibromatosis type 1, …See details»
NFlection Therapeutics Announces Orphan Drug ... - Business Wire
Aug 18, 2021 · NFlection’s topical MEK inhibitors are designed to degrade rapidly in circulation to avoid systemic side effects. To learn more about the company, please visit www.nflectionrx.com.See details»
NFlection Therapeutics - Overview, News & Similar companies
Jan 10, 2023 · NFlection Therapeutics contact info: Phone number: (617) 875-4559 Website: www.nflectionrx.com What does NFlection Therapeutics do? NFlection Therapeutics focuses …See details»
NFlection Therapeutics' NFX-179 Gel Demonstrates Safety and …
WAYNE, Pa., May 26, 2021 /PRNewswire/ -- NFlection Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of targeted therapies for rare …See details»
NFlection Therapeutics Launches with $20M Series A Funding to …
WAYNE, Pa., June 9, 2020 – NFlection Therapeutics, Inc., a biopharma therapeutics developer dedicated to targeting disease pathways to uncover new approaches to fighting rare disease, …See details»
Investors - NFlection Therapeutics
© 2024 NFlection Therapeutics Inc. All Rights Reserved. Explore. About Us; Science; News; ContactSee details»
Improving the Lives of People with Neurofibromatosis - NF Midwest
Jul 13, 2022 · patients.nflectionrx.com SCAN ME ABOUT US NFlect10n Is dedE¾Sto safe mm-surgeal in the dlsccwrg tar*ted rare dlson*rs RAS . About NFX.179 Topical Gel NFX-17g …See details»
NFlection Therapeutics’ NFX-179 Gel Demonstrates Safety
May 26, 2021 · NFlection’s topical MEK inhibitors are designed to degrade rapidly in circulation to avoid systemic side effects. To learn more about the company, please visit www.nflectionrx.com.See details»
InflectionCX
InflectionCX brings together decades of expertise and cutting-edge technology to deliver modern Customer Experiences. We leverage the latest in digital and AI technologies coupled with our …See details»
News - NFlection Therapeutics
Topical MEK Inhibitor, NFX-179, Prevents Cutaneous Squamous Cell Carcinoma in Pre-Clinical Model.See details»